Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2241 to 2250 of 2588 total matches.
The Viralizer For The Common Cold
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Desflurane - A New Volatile Anesthetic
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993 (Issue 895)
. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.
Pallidotomy for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Dec 06, 1996 (Issue 989)
. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Ablation of the globus pallidus, an old treatment for Parkinsons disease, is being tried again, using more refined stereotactic techniques, improved brain imaging and new methods for recording neuronal activity (CW Olanow, Ann Neurol, 40:341, September 1996).
Safety of Dronedarone (Multaq)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
for oral treatment
of paroxysmal or persistent (non-permanent) atrial
fibrillation or atrial flutter.1 ...
Dronedarone (Multaq – Sanofi), an analog of amiodarone,
was approved by the FDA in 2009 for oral treatment
of paroxysmal or persistent (non-permanent) atrial
fibrillation or atrial flutter. Amiodarone (Cordarone, and
others) is more effective for this indication, but its use is
often limited by its adverse effects, including thyroid and
pulmonary toxicity.
Prosthetic Heart Valves
The Medical Letter on Drugs and Therapeutics • Aug 20, 2012 (Issue 1397)
than those in the aortic position.1
Mechanical valves are preferred for younger patients
( ...
Prosthetic heart valves have been used effectively in
patients with mitral and aortic valvular heart disease
for more than 50 years, but no replacement valve
developed to date is suitable for all types of patients.
In Brief: Anktiva for Bladder Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
) are
also approved for the same indication.1
underwent transurethral resection of the tumor
before ...
Nogapendekin alfa inbakicept-pmln (Anktiva –
ImmunityBio), a first-in-class interleukin-15 (IL15)
receptor agonist, has been approved by the FDA for
use with Bacillus Calmette-Guérin (BCG) for treatment
of patients with BCG-unresponsive nonmuscle
invasive bladder cancer (NMIBC) with carcinoma in
situ with or without papillary tumors. Such patients
generally undergo bladder tumor resection, followed
by intravesical BCG treatment, but treatment failure
and cancer recurrence are common. The adenoviral
vector-based intravesical gene therapy nadofaragene
firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6 doi:10.58347/tml.2024.1705e | Show Introduction Hide Introduction
Vasodilators For Congestive Heart Failure
The Medical Letter on Drugs and Therapeutics • Jan 29, 1988 (Issue 758)
(WHW Inman and NSB Rawson, Lancet, 1:872,
1987).
PRAZOSIN — A postsynaptic alpha-adrenergic-receptor ...
Vasodilators are widely used for treatment of congestive heart failure (CHF) that has not responded adequately to diuretics and digitalis. Vasodilator drugs redistribute blood volume in patients with heart failure, lowering pressure and reducing volume in the failing left ventricle, which leads to increased cardiac output, decreased pulmonary capillary wedge pressure, and improved exercise tolerance. Since the last Medical Letter review of this subject (Volume 26, page 115, 1984), some additional data have become available.
Prevention of Pneumocystis Carinii Pneumonia
The Medical Letter on Drugs and Therapeutics • Oct 07, 1988 (Issue 776)
with aerosolized pentamidine (30 or 150 mg twice monthly or
300 mg once monthly) for an average of 3
1
/2 months ...
Pneumocystis carinii pneumonia (PCP) is a common cause of death in patients with acquired immune deficiency syndrome (AIDS). PCP is the first serious opportunistic infection in more than 60% of patients with AIDS, and about 80% of AIDS patients develop PCP at least once (AE Glatt et al, N Engl J Med, 318:1439, June 2, 1988). Many studies using drugs to prevent PCP in patients with AIDS have recently been reported.
Octreotide - A Synthetic Somatostatin
The Medical Letter on Drugs and Therapeutics • Jul 14, 1989 (Issue 796)
that resist degradation
by serum peptidases. It has a half-life of about 1.5 hours and can be giv- en ...
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas (vasoactive intestinal peptide-secreting tumors).
Olsalazine
The Medical Letter on Drugs and Therapeutics • Nov 16, 1990 (Issue 831)
) similar to sulfasalazine (1 gram bid) in preventing relapse of ulcerative colitis in 164 patients treated ...
Olsalazine sodium (Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine (Azulfidine; and others).